StockNews.AI
XRAY
StockNews.AI
202 days

DENTSPLY ALERT: Bragar Eagel & Squire, P.C. is Investigating DENTSPLY SIRONA Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. Dentsply is under investigation for possible fiduciary duty breaches. 2. Class action alleges inadequate patient care and undisclosed injuries from Byte. 3. Reports of serious injuries linked to Byte aligners have increased significantly. 4. Allegations suggest Dentsply misrepresented business operations during the Class Period.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Dentsply faces serious legal challenges, which could lead to financial penalties. Historical legal issues have often resulted in significant drops in stock prices.

How important is it?

The investigation may harm Dentsply's market reputation and stock performance. Legal issues are crucial for investor perception and confidence.

Why Short Term?

The outcome of the investigation could affect investor confidence immediately. Legal matters typically have quick impacts on stock valuation.

Related Companies

XRAY
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on behalf of long-term stockholders following a class action complaint that was filed against Dentsply on November 26, 2024 with a Class Period from May 6, 2021 to November 6, 2024. Our investigation concerns whether the board of directors of Dentsply have breached their fiduciary duties to the company. The complaint alleges that Defendants failed to disclose that: (1) Dentsply targeted low-income people who did not have access to good oral hygiene education, a dentist, or dental insurance, which often meant patients signing up for Byte had underlying dental issues that would have made them ineligible for treatment; (2) the push for Byte growth and sales commissions caused sales employees to sell to contraindicated patients; (3) as a result of the above, the Byte patient onboarding workflow did not provide adequate assurance that contraindicated patients did not enter treatment; (4) before and during the Class Period, reports of Byte patient injuries were pouring in; (5) Dentsply knew that its Byte aligners were causing severe patient injuries for years but did little to investigate those injuries or notify the FDA; (6) Dentsply had no systems in place to notify the FDA of these injuries, which the Company is required to do within 30 days of learning of a problem; (7) the FDA had received a sharp uptick in reports of serious injuries from Byte patients; (8) as a result of the above, Dentsply materially overstated the goodwill value of Byte; (9) as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. If you are a long-term stockholder of Dentsply, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News